Analysis on sarcoglycans expression as markers of septic cardiomyopathy in sepsis-related death
The post-mortem assessment of sepsis-related death can be carry out by many methods recently suggested as microbiological and biochemical investigations. In these cases, the cause of death is a multiple organ dysfunction due to a dysregulated inflammatory response occurring after the failure of infection control process. It was highlighted also that the heart can be a target organ in sepsis which determines the so-called septic cardiomyopathy characterized by myocardial depression. Several mechanisms to explain the pathophysiology of septic cardiomyopathy were suggested, but very few studies about the structural alterations of cardiac cells responsible for myocardial depression were carried out. The aim of this study was to evaluate whether sarcoglycans (SG) were involved in septic cardiac damage analyzing their expression in sepsis-related deaths and, particularly, if these proteins can be used as markers of septic myocardial dysfunction. Cases of septic-related death confirmed by clinical and autopsy records were investigated and compared to a control group of traumatic deaths. Indirect immunofluorescence analysis was performed to analyze α-SG, β-SG, δ-SG, ζ-SG, ε-SG, and γ-SG. Decrease of fluorescence staining pattern for all tested sarcoglycans was observed in the septic-related deaths compared to normal fluorescence staining pattern of control group. These results provide new findings about the myocytes structural alterations due to sepsis and suggest that these proteins could be used in forensic assessment of septic cardiomyopathy.
KeywordsForensic pathology Sepsis Septic cardiomyopathy Sarcoglycans Immunofluorescence
Compliance with ethical standards
For this type of study, formal consent is not required.
- 1.Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, Rubenfeld G, Kahn JM, Shankar-Hari M, Singer M, Deutschman CS, Escobar GJ, Angus DC (2016) Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8):762–774CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R (2013) Surviving sepsis campaign guidelines committee including the pediatric subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228CrossRefPubMedGoogle Scholar
- 27.Lim LE, Duclos F, Broux O, Bourg N, Sunada Y, Allamand V, Meyer J, Richard I, Moomaw C, Slaughter C, Tomé FMS, Fardeau M, Jackson CE, Beckmann JS, Campbell KP (1995) Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. Nat Genet 11(3):257–265CrossRefPubMedGoogle Scholar
- 28.Nigro V, Piluso G, Belsito A, Politano L, Puca AA, Papparella S, Rossi E, Viglietto G, Esposito MG, Abbondanza C, Medici N, Molinari AM, Nigro G, Puca GA (1996) Identification of a novel sarcoglycan gene at 5q33 encoding a sarcolemmal 35 kDa glycoprotein. Hum Mol Genet 5(8):1179–1186CrossRefPubMedGoogle Scholar
- 30.Duclos F, Straub V, Moore SA, Venzke DP, Hrstka RF, Crosbie RH, Durbeej M, Lebakken CS, Ettinger AJ, van der Meulen J, Holt KH, Lim LE, Sanes JR, Davidson BL, Faulkner JA, Williamson R, Campbell KP (1998) Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. J Cell Biol 142(6):1461–1471CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Cutroneo G, Centofanti A, Speciale F, Rizzo G, Favaloro A, Santoro G, Bruschetta D, Milardi D, Micali A, Di Mauro D, Vermiglio G, Anastasi G, Trimarchi F (2015) Sarcoglycan complex in masseter and sternocleidomastoid muscles of baboons: an immunohistochemical study. Eur J Histochem 59(2):2509CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Cutroneo G, Vermiglio G, Centofanti A, Rizzo G, Runci M, Favaloro A, Piancino MG, Bracco P, Ramieri G, Bianchi F, Speciale F, Arco A, Trimarchi F (2016) Morphofunctional compensation of masseter muscles in unilateral posterior crossbite patients. Eur J Histochem 60(2):2605CrossRefPubMedPubMedCentralGoogle Scholar
- 46.Goldhaber JI, Kim KH, Natterson PD, Lawrence T, Yang P, Weiss JN (1996) Effects of TNF-alpha on [Ca2+]i and contractility in isolated adult rabbit ventricular myocytes. Am J Phys 271(4 Pt 2):H1449–H1455Google Scholar
- 49.Zhong J, Hwang TC, Adams HR, Rubin LJ (1997) Reduced L-type calcium current in ventricular myocytes from endotoxemic Guinea pigs. Am J Phys 273(5 Pt 2):H2312–H2324Google Scholar
- 67.Sakamoto A, Ono K, Abe M, Jasmin G, Eki T, Murakami Y, Masaki T, Toyo-oka T, Hanaoka F (1997) Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci U S A 94(25):13873–13878CrossRefPubMedPubMedCentralGoogle Scholar